"What is your expectation about Apabetalone being accepted for ASN late breaking presentation?  Although AHA accepted us, that was for a Phase 3 trial.  ASN on the other hand is looking at a sub study of a trial.  Does that change the perception of ASN's willingness to accept our presentation?"

Good questions. I'll let you know on Friday when they announce the late breakers. Lol.

"If ASN does not accept RVX, can the same data be dumped on the AHA?  I note that we only have 8 minutes to make our case at the AHA."

At this point we don't even know if Resverlogix submitted anything for ASN. In my opinion, AHA and other cardio conferences are not good venues to present the CKD sub-study data. If not at ASN, they might just announce results and present detailed data sometime later like at June 2020 ERA-EDTA or ADA. We'll surely know more in the next two weeks after ASN late breakers are announced and after Resverlogix presents at BIO Investor. 

BearDownAZ